Related Experiment Video
Updated: Jun 10, 2026
Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
Published on: May 17, 2015
Changes in surface expression of platelet membrane glycoproteins and progression of heart transplant vasculopathy
S Fateh-Moghadam1, W Bocksch, A Ruf
1Innere Medizin, Kardiologie, Charité-Campus Virchow and Deutsches Herzzentrum Berlin, Humboldt Universität zu Berlin, Germany.
Insights
Enhanced platelet activation, indicated by ligand-induced binding site 1 (LIBS-1), is linked to transplant vasculopathy progression. This finding may guide future prevention strategies for heart transplant recipients.
Area of Science:
- Cardiology
- Immunology
- Transplantation Science
Background:
- Transplant vasculopathy significantly limits long-term heart transplant success.
- The role of platelets in transplant vasculopathy development and progression requires further elucidation.
Purpose of the Study:
- To investigate the association between platelet activation markers and transplant vasculopathy in heart transplant recipients.
- To determine if platelet activation predicts the presence and progression of transplant vasculopathy.
Main Methods:
- 78 heart transplant recipients underwent platelet analysis and intracoronary ultrasound.
- Platelet activation was measured using immunological surface markers (LIBS-1, P-selectin, GPIIb-IIIa) via flow cytometry.
- Quantitative intracoronary ultrasound assessed disease severity at baseline and 1-year follow-up.
Main Results:
- Increased ligand-induced binding site 1 (LIBS-1) immunoreactivity correlated with diffuse transplant vasculopathy.
- LIBS-1 was an independent predictor for the presence and progression of diffuse transplant vasculopathy.
- Elevated LIBS-1 levels significantly increased the relative risk for diffuse transplant vasculopathy presence and progression.
Conclusions:
- Enhanced platelet activation is strongly associated with transplant vasculopathy development and progression.
- Understanding these mechanisms could lead to novel treatment strategies for preventing transplant vasculopathy.
Background:
Transplant vasculopathy is the main limiting factor of the long-term success of heart transplantation. We sought to establish the role of platelets in the development and progression of transplant vasculopathy.
Methods And Results:
Platelet analysis and intracoronary ultrasound examination were performed in 78 heart transplant recipients. Quantitative intracoronary ultrasound was used to define the severity of disease at baseline (48.8+/-4.5 months after transplantation) and at 1-year follow-up. Platelet activation was assessed with the use of immunological surface markers of activation (ligand-induced binding site 1 [LIBS-1], P-selectin, GPIIb-IIIa) and flow cytometry. We found that LIBS-1 immunoreactivity was significantly increased in patients with diffuse disease when compared with focal transplant disease (median [quartile], 27[14, 64] versus 18[7.9, 47], P=0.04). In a logistic regression model, we found that LIBS-1 was an independent predictor for the presence and progression of diffuse transplant vasculopathy (P=0.04). Patients with enhanced LIBS-1 levels (>75% quartile) had a 3.3-fold increased relative risk (95% CI 1.8 and 18.9, P=0.002) for the presence of diffuse transplant vasculopathy. When a cutoff value of 16.5 for the level of LIBS-1 was used, patients had a 4.8-fold increased relative risk (95% CI 1.9 and 12.5, P<0.01) for the progression of transplant vasculopathy.
Conclusions:
Enhanced platelet activation is strongly associated with the development and progression of transplant vasculopathy. Understanding the underlying pathophysiological mechanisms might contribute to the development of treatment strategies to prevent transplant vasculopathy.
